Efficacy of injectable carbapenems for respiratory infections caused by Streptococcus pneumoniae and Haemophilus influenzae with Monte Carlo Simulation

Japanese Journal of Antibiotics

Volumn 60, Issue 1, 2007, Pages 47-57

  Mikamo, Hiroshige ^a,b   Tanaka, Kaori ^a   Watanabe, Kunitomo ^a  

^a GIFU UNIVERSITY   (Japan)

^b GIFU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIAPENEM; CILASTATIN PLUS IMIPENEM; MEROPENEM; PANIPENEM PLUS BETAMIPRON;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; DRUG EFFICACY; DRUG METABOLISM; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MONTE CARLO METHOD; NONHUMAN; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

CARBAPENEMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; IMMUNOCOMPROMISED HOST; INJECTIONS; MONTE CARLO METHOD; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 33947398873     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Japanese source
2. KUTI, J. L.; P. D. DANDEKAR & C. H. NIGHTINGALE: Use of Monte Carlo Simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43: 1116-1123, 2003
3. LOMAESTRO, B. M. & G. L. DRUSANO: Pharmacodynamic evaluation of extending the administration time of meropenem using Monte Carlo Simulation pharmacodynamic. Antimicrob. Agents Chemother. 49: 461-463, 2005
4. KUTI, J. L.; C. H. NIGHTINGALE & D. P. NICOLAU: Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Date collected in North America in 2002. Antimicrob. Agents Chemother. 48: 2464-2476, 2004
5. SUN, H. K.; J. L. KUTI & D. P. NICOLAU: Pharmacodynamics of antimicrobial for the empirical treatment of nosocomial pneumonia:A report from the OPTAMA program. Crit. Care Med. 33: 2222-2227, 2005
6. KRUEGER, W. A.; J. B. MARTINA, KINZIG- SCHIPPERS, et al.: Evaluation by Monte Carlo Simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother. 49: 2464-2476, 2005
7. Jpn. J. Antibiotics 58: 359-367, 2005
8. Jpn. J. Antibiotics 57: 172-186, 2004
9. Jpn. J. Antibiotics 58: 290-302, 2005
10. Chemotherapy 40(S-1): 258-275, 1992
11. Chemotherapy 33(S-4): 379-391, 1985
12. Chemotherapy 39(S-3): 242-264, 1991
13. Chemotherapy 42(S-4): 277-284, 1994
14. Japanese source
15. Jpn. J. Antibiotics 51: 532-534, 1998
16. Jpn. J. Antibiotics 57: 70-104, 2004
17. Jpn. J. Antibiotics 58: 655-689, 2005
18. ISHIDA, T.; T. HASHIMOTO, M. AKITA, et al.: Etiology of community-acquired pneumonia in hospitalization patients, a 3-year prospective study in Japan. Chest 114: 1588-1593, 1998
19. Japanese source
20. RELLO, J.; M. GALLEGO, D. MARISCAL, et al.: The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156: 196-200, 1997
21. KOLLEF, M. H. & S. WARD: The influence of Mini-BAL cultures on patient outcomes. Chest 113: 412-420, 1998
22. KOLLEF, M. H.; G. SHERMAN, S. WARD, et al.: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically III patients. Chest 115: 462-474, 1999
23. KOLLEF, M. H.: Gram-negative bacterial resistance: Evolving patterns and treatment paradigms. Clin. Infect. Dis. 40 (Suppl. 2): S85-S88, 2005
24. IBRAHIM, E. H.; G. SHERMAN, S. WARD, et al.: The influence of inadequate antimicrobial treatment of blood-stream infections on patient outcomes in the ICU setting. Chest 118: 146-155, 2000
25. LUNA, C. M.; M. V. PATRICIA, S. NIEDERMAN, el al.: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111: 676-685, 1997
26. RELLO, J. & A. RODRIGUEZ: Improving survival for sepsis: On the cutting edge. Crit. Care Med. 31: 2807-2808, 2003
27. JOSE, GARNACHO-MONTERO.; GARCIA- GARMENDIA. JOSE LUIS & BARRERO- ALMODOVAR. ANA, et al.: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Clit. Care Med. 31: 2742-2751, 2003
28. CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosings of mice and men. Clin. Infect. Dis. 26: 1-12, 1998
29. CRAIG, W. A.: The role of pharmacodynamics in effective treatment of community-acquired pathogens. Advanced Studies Med. 2: 126-134, 2002
30. DRUSANO, G. L.: Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36 (Suppl. 1):S42-S50, 2003
31. Jpn. J. Antibiotics 59: 459-467, 2006